Veradermics, Incorporated (MANE) Stock Score, Valuation & Financial Research

Veradermics, Incorporated is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MANE

Veradermics, Incorporated does not currently have a complete Wall Street Score. The stored market price is USD 117.63. These figures are a research snapshot, not a buy or sell recommendation.

What Veradermics, Incorporated does

Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Veradermics is a late clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model is focused on the research and development of innovative therapeutics for dermatological conditions, specifically pattern hair loss, and it relies on capital raises to fund its ongoing clinical trials and operations.

Products and services

The company is developing VDPHL01, an investigational oral non-hormonal treatment for pattern hair loss in both male and female patients.

Brands and product families

VDPHL01 — Investigational oral non-hormonal treatment for pattern hair loss. Source

Customer types

Physicians; Tele-dermatologists.

Suppliers, materials and equipment

Contract Research Organizations (CROs) — The company relies on unnamed third-party contract research organizations to conduct its clinical trials. Source
Contract Manufacturing Organizations (CMOs) — The company relies on unnamed third-party contract manufacturing organizations for the production of its clinical trial materials. Source

Business strengths to evaluate

Dermatologist-founded leadership with specialized focus on aesthetic and dermatological conditions Source

Business risks and research considerations

History of operating losses and expectation of continued losses Source
Dependence on the successful clinical development and regulatory approval of VDPHL01 Source
Reliance on third-party manufacturers and clinical research organizations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MANE financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: Not currently available
Stored price:: USD 117.63
Market capitalization:: 4.91B (currency not supplied)
Revenue:: USD 0.00
Net income:: USD -92.68M
Free cash flow:: USD -71.63M
Cash:: USD 319.33M
Total debt:: USD 428K
EPS:: USD -2.14

What stands out

Free cash flow is USD -71.63M, negative for the stored period.
The balance sheet shows USD 319.33M of cash versus USD 428K of total debt, an excess of cash over debt on these two reported measures.
The current research record carries a limited financial history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Cash exceeds debt by USD 318.91M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MANE

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

How long can MANE fund negative free cash flow using its current cash position before it may need more debt or new shares?
How is MANE likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
What specifically needs to improve for MANE to reach sustainable profitability?
What does the current limited financial history warning mean for the reliability or interpretation of MANE's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research MANE

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.